Needham Maintains Buy on Cellebrite DI, Raises Price Target to $13.5
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Cikos has maintained a Buy rating on Cellebrite DI (NASDAQ:CLBT) and increased the price target from $13 to $13.5.
March 28, 2024 | 10:26 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Cikos reaffirmed a Buy rating on Cellebrite DI and raised the price target to $13.5 from $13.
The increase in the price target by a reputable analyst suggests a positive outlook on the stock, likely leading to increased investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100